Reduction of exercise capacity in sarcoidosis in relation to disease severity

Anastasios Kallianos¹
Paul Zarogoulidis²
Fotini Ampatzoglou²
Georgia Trakada²,³
Elias Gialafos⁴
Georgia Pitsiou²
Athanasia Patakα²
Lemonia Veletza²
Konstantinos Zarogoulidis²
Wolfgang Hohenforst-Schmidt⁵
Dimitris Petridis⁶
Ioannis Kioumis²
Aggeliki Rapti¹

¹2nd Pulmonary Department, Sotiria Chest Diseases Hospital, Athens; ²Pulmonary Department-Oncology Unit, “G Papanikolaou” General Hospital, Aristotle University of Thessaloniki, Thessaloniki; ³Sarcoïd Laboratory, Therapeutic Clinic Alexander Hospital, University of Athens, Athens; ⁴Heart Diseases Department Aiginio Hospital, University of Athens, Athens, Greece; ⁵Medical Clinic I, “Fuerth” Hospital, University of Erlangen, Fuerth, Germany; ⁶Department of Food Technology, School of Food Technology and Nutrition, Alexander Technological Educational Institute, Thessaloniki, Greece

Introduction: Pulmonary function tests (PFTs) do not always predict functional limitations during exercise in sarcoidosis. Cardiopulmonary exercise testing (CPET) may facilitate the recognition of exercise intolerance in these patients.

Aim: As relevant data in sarcoid patients are limited, the aim of the study reported here was to assess exercise capacity impairment during a maximal CPET and to evaluate potential correlations with PFT measurements and radiological stages of the disease.

Method: A total of 83 sarcoid patients consecutively referred for evaluation of exertional dyspnea over a 3-year period were studied retrospectively with PFTs, including spirometry, diffusing capacity of the lung for carbon monoxide (DLCO) and lung volumes, and CPET using standard protocol. Patients were grouped according to their radiological stages: Stage I (n=43), Stages II–III (n=31), and Stage IV (n=9).

Results: Forced expiratory volume in 1 second, forced vital capacity, and total lung capacity were mildly impaired only in Stage IV (means ± standard deviation: 7.44±28.00, 71.33±26.70, and 59.78±21.72, respectively), while DLCO was mildly and moderately reduced in Stages II–III and IV (72.68±14.13 and 51.22±18.50, respectively) and differed significantly between all stages (I vs II–III: P=0.003, I vs IV: P=0.003, and II–III vs IV: P=0.009). Exercise capacity (as expressed by peak oxygen consumption <84% predicted) was decreased in 53% of patients (Stage I: 48%, Stages II–III: 52%, Stage IV: 78%); however, significant differences were noticed only between Stages I and IV (P=0.0025). Of note, significant correlations were found between peak oxygen consumption and DLCO (P=0.0083), minute ventilation (P<0.0001), oxygen pulse (P<0.0001), lactate threshold (P<0.0001), and peak ventilatory threshold (P<0.0001).

Conclusion: CPET could be considered a useful tool in exercise intolerance evaluation in sarcoid patients with mild PFT abnormalities. Exercise limitation in sarcoidosis may be attributed to both ventilatory and cardiocirculatory impairment.

Keywords: cardiopulmonary exercise testing, pulmonary function tests, exercise

Introduction

Sarcoidosis is a heterogeneous multisystem granulomatous disease of unknown etiology, with variable clinical presentations depending on the organs affected.¹² Pulmonary involvement is the most frequent manifestation and patients may often exhibit fatigue, dyspnea on exertion, and impaired exercise tolerance.³⁴ Assessment of functional impairment with pulmonary function tests (PFTs) typically reveals a restrictive pattern with a reduction in diffusing capacity for carbon monoxide (DLCO),³ while airflow limitation may be observed in a significant proportion of patients.⁶

Several studies, however, have shown inconsistencies between symptoms and abnormalities in PFTs in sarcoid patients, as normal spirometry and DLCO at rest do not categorically exclude functional limitations during exercise.⁷⁸ Cardiopulmonary exercise testing (CPET), on the other hand, appears to be more useful in the...
recognition of exercise intolerance, even in the early stages of the disease.⁹,¹⁰

Therefore, as relevant data in sarcoidosis are limited, the aim of the study presented here was to examine the possible added role of a maximal CPET, compared to PFT and DLCO measurements, in the evaluation of exercise capacity impairment in sarcoid patients with complaints of dyspnea and exercise limitation and to assess any potential correlations with PFT measurements and radiological stages of the disease.

**Methods**

**Subjects**

Eighty-three Caucasian adult patients, who were consecutively referred for evaluation of dyspnea and exercise limitation to a referral center for sarcoidosis over a 3-year period, were studied. The diagnosis of sarcoidosis was based on clinical features, radiological findings, and histological evidence of non-caseating granulomata, according to the World Association of Sarcoidosis and Other Granulomatous Disorders guidelines.¹ Subjects’ chest radiographs were examined by two radiologists blinded to the patient’s history and classified as: Stage 0: no radiographic abnormalities, Stage I: bilateral hilar adenopathy without parenchymal abnormalities, Stage II: bilateral hilar adenopathy with interstitial parenchymal infiltrates, Stage III: interstitial parenchymal infiltrates without hilar adenopathy, or Stage IV: evidence of pulmonary fibrosis with cicatricial changes, in accordance with the World Association of Sarcoidosis and Other Granulomatous Disorders guidelines.²

The reason for performing CPET was disabling symptoms of persistent dyspnea and exercise limitation at the time of diagnosis or during follow-up that could not be explained by the results of routine investigation, including lung function tests or chest radiographs. Patients suffering from anemia or significant comorbidities (eg, cardiac, other respiratory or neuromuscular disorders) were excluded from the study. Clinical and laboratory data and PFT and CPET results were collected from medical records and studied retrospectively. The study was approved by the Investigational Review Board of the Therapeutic Clinic Alexandra Hospital, University of Athens, and informed consent was obtained from all the participants.

**Dyspnea evaluation**

Quantification of the perception of dyspnea was assessed at the time of evaluation via the modified British Medical Research Council (MRC) self-administered questionnaire.¹¹ The MRC scale classifies subjects into one of five categories according to their degree of dyspnea when performing certain activities; scores range from 0 to 4, with the higher scores indicating more severe dyspnea. Patients with MRC 0 were excluded from the study.

**PFTs**

Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV₁), the FEV₁ to FVC ratio, mid-expiratory flow (forced expiratory flow 25%–75% [FEF₂₅₋₇₅]), total lung capacity (TLC), residual volume (RV), and functional residual capacity (FRC) were measured by plethysmography with a Jaeger® Masterlab cabinet. All the tests were performed in sitting position and the best of three attempts was evaluated. The tests were compatible with the European Respiratory Society statement for Coal and Steel.¹² DLCO was measured using the single-breath method, after adjusting for hemoglobin concentration in g·dL⁻¹, according to Cotes’ equation and predicted values were derived from standard equations.¹³

**Maximal exercise capacity**

CPET was performed using a standard protocol.¹⁴ All of the patients underwent a symptom-limited incremental exercise test on an upright, electrically braked cycle ergometer (Viasys Oxycon Pro®) and were monitored during the testing, in terms of electrocardiography (by 12-lead electrocardiogram), arterial pressure, and oxygen saturation (by pulse oximetry) every 2 minutes. The expired gases were analyzed with the ergospirometer following collection of 2 to 5 minutes of rest data, subjects pedaled at a rate of 50–60 rpm/min for 3 minutes without resistance, after which the work rate was incremented for 10–20 watts (W) each minute. The patients were encouraged to perform maximally for 8 to 12 minutes; otherwise, the test was terminated at the point of symptom limitation. Peak work rate (W), peak oxygen consumption (VO₂ peak), peak carbon dioxide production (VCO₂ peak), minute ventilation (V′ₜₐ₉), tidal volume (Vₜ), heart rate (HR), breathing frequency, oxygen pulse and oxygen uptake/work rate ratio (ΔVO₂/ΔWR) were recorded. Anaerobic threshold (AT) was determined by V-slope method and reported as the percentage of predicted VO₂ peak. A result below 80% of the predicted values was assumed to indicate physical impairment, while maximum oxygen consumption (VO₂ max) below 83% of the predicted value indicated impaired exercise intolerance.¹⁴

**Statistical analysis**

All variables are expressed as means ± standard deviation and, when appropriate, in absolute numbers or percentages. The
normal distribution of the variables was evaluated with the Kolmogorov–Smirnov analysis. PFT and CPET data, subdivided into groups according to the radiological stage of the disease, were compared using paired t-test or Mann–Whitney U-test, as appropriate. Correlations between VO$_2$ peak and clinical, functional, and CPET variables were calculated using Spearman’s rank coefficient. A $P$-value of <0.05 was considered significant. Data were analyzed using SPSS software (v 18.0; IBM Corporation, Armonk, NY, USA).

## Results

### Clinical characteristics and resting PFT

Eighty-three patients, 52 of whom were female, with a mean age 58.02±11.75 years (range 36–84 years) were included. The mean time from diagnosis was 13.27±6.6 years. Smoking history (current or ex-smokers) was recorded for 14 (17%) patients. Twenty-four patients (29%) had a score of 1 point on the MRC scale, while 37 (45%) and 22 (26%) patients had scores of 2 and 3 points, respectively. There were no Stage 0 patients and Stages I, II, III, and IV included 43 (52%), 25 (30%), six (7%), and nine (11%) patients, respectively. Since lung function indices were not statistically different between Stages II and III, patients were grouped according to their radiological stages as Group 1 (Stage I), Group 2 (Stages II and III), and Group 3 (Stage IV). There were no differences between groups in regard to age and sex. Mean serum angiotensin-converting enzyme level was 43.04±19.89 and, although there was no significant difference between groups, higher levels of serum angiotensin-converting enzyme were found in Stage I vs Stages II–III and IV, however values indicative of clinical impairment (<80% of predicted values) were noticed only in Stage IV (72.44±28.00, 71.33±26.70, and 59.78±21.72, respectively). DLCO was found within normal limits in Stage I and mildly and moderately reduced in Stages II–III and IV (72.68±14.13 and 51.22±18.50, respectively) and differed significantly between all groups (Stage I vs Stages II–III, $P=0.003$; Stage I vs Stage IV, $P=0.003$; and Stages II–III vs Stage IV, $P=0.009$).

### CPET results

Peak HR $\geq$85% of the predicted value was achieved in 74% of the patients. According to the radiological stages, Stages I, II–III, and IV, the peak HR was achieved by 72%, 74%, and 68% of patients, respectively. With respect to AT, a maximal CPET was performed by 81% of patients. Leg fatigue alone was the cause of exercise intolerance in 46% of patients, while dyspnea was the main complaint in the remaining patients.

The CPET results in the studied population, subdivided in relation to disease stages, are summarized in Table 2. An abnormal CPET (VO$_2$ peak <83%) was exhibited by 53% of patients while, according to the radiological stages, VO$_2$ peak was decreased in 48% of patients in Stage I and in 52% and 78% of patients in Stages II–III and IV, respectively. However, significant differences in exercise capacity were noticed only between Stages I and IV ($P=0.003$). $V_{E}/V_{CO_2}$ was significantly increased in Stage IV compared to in Stage I patients (30.73±6.26 vs 25.58±4.05, $P<0.001$), while the other ventilatory ($V_{E}$, max, breathing frequency and $V_{E}/VO_2$) and cardiocirculatory parameters (HR peak,

### Table 1

| Characteristic | All (n=83) | Stage I (n=43) | Stages II–III (n=31) | Stage IV (n=9) | $P$-value |
|----------------|-----------|----------------|---------------------|---------------|-----------|
| Age, years     | 58.02±11.75 | 57.16±12.20 | 58.84±11.59 | 59.33±11.00 | 0.5270     |
| SACE, IU       | 43.04±19.89 | 42.16±18.83 | 46.13±21.30 | 36.56±20.11 | 0.4930     |
| FVC            | 93.71±18.23 | 101.0±12.22 | 89.8±16.23 | 72.4±28.00 | 0.0040     |
| FEV$_1$        | 90.36±17.89 | 97.05±12.53 | 86.6±16.67 | 71.33±26.70 | 0.0070     |
| FEV$_1$/FVC    | 90.94±10.23 | 90.05±8.69 | 90.93±11.81 | 97.11±10.19 | 0.0810     |
| FEF$_{25-75}$  | 79.29±22.29 | 85.23±17.35 | 77.55±21.85 | 52.89±30.92 | 0.0150     |
| FRC            | 89.90±18.21 | 93.25±19.26 | 92.25±17.27 | 85.28±23.65 | 0.0360     |
| RV             | 82.95±19.44 | 89.19±16.83 | 82.06±16.89 | 65.78±29.79 | 0.0600     |
| TLC            | 82.31±15.42 | 88.81±10.34 | 79.84±12.46 | 59.78±21.72 | 0.0120     |
| DLCO           | 79.02±19.27 | 89.42±14.52 | 72.68±14.13 | 51.22±18.50 | 0.0003     |

Note: All parameters are expressed as mean ± standard deviation. Results of pulmonary function tests are expressed as percentages of predicted values.

Abbreviations: DLCO, diffusing capacity of the lung for carbon monoxide; FEF$_{25-75}$, forced expiratory flow 25%–75%; FEV$_1$, forced expiratory volume in 1 second; FRC, functional residual capacity; FVC, forced vital capacity; RV, residual volume; SACE, serum angiotensin-converting enzyme; TLC, total lung capacity.
O₂ pulse, ΔHR/ΔVO₂ and ΔVO₂/ΔWR) did not differ among the three groups.

Among the whole population, significant correlations (P<0.001) were found between VO₂ peak and age, DLCO, Vₐ, oxygen pulse, lactate threshold, and Vₐ peak (Figure 1). Correlations of VO₂ peak in relation to the radiological stages of the disease are summarized in Table 3. Of note, both functional parameters (FEV₁, FVC, FEF₂₅₋₇₅) and HR peak were found to be significant predictors of exercise capacity only in Stages II+II, whereas exercise limitation in Stage IV was related mainly to physiological impairment due to ventilatory parameters.

Moreover, the spirometric and ergo-spirometric variables, seen as two variable sets, were correlated with each other to produce the correlation matrix. Apparently, transfer factor for the lung for carbon monoxide (TLCO%) and diffusing capacity of the lung for carbon monoxide (DLCO%) correlate adequately with the spirometric percent forced expiratory volume in 1 second (FEV₁, %) and percent forced vital capacity (FVC%), all in a positive direction. Loose correlations among other variables can also be viewed between the two sets of variables. Figures 2 and 3 show the arrangement of variables and patients (sample) in the space formed by the principal component analysis (PCA) major axes 1 and 2. Each quartile hosts particular variables and patients in the two graphs correspondingly, and thus it is directly informative for their behavior. The variables VO₂ max toward VE, positioned on the lower right quartile (Figure 2), correlate strongly and positively with each other and explain patients who fulfill the conditions, the absence of extrapulmonary sarcoidic location, and the restriction rule at radiological Stage 1 (Figure 3). On the contrary, variables such as VE/VO₂, VE/VO₂ peak, and deadspace/tidal volume ratio (Ve/Vt) cover the lower left quartile (Figure 1) indicate the worst radiological stage, present the extrapulmonary location, and illustrate the restriction rule (Figure 3). The variables and particularly the VE/VO₂ are negatively correlated with the variables possessing the upper right quartile, in which normal conditions prevail. The radiological stages exert statistically significant effects on some of the ergo-spirometric variable spectrum. These effects are illustrated per variable in Figure 4 where two inverse trends are formed. A group of three variables (VE/VO₂, Vₐ, tidal volume; VT, ventilatory threshold; WR, workload) show an increasing response and more intensity at Stage III and a group of eight variables decline at increasing radiological levels and more profoundly at Stage III.

The restriction rule and radiological stages interact significantly (χ²=18.39, P<0.001) resulting in a high present restriction ruling effect at Stage III that is nearly absent at Stage I. DLCO, transformed to ordinal values of low, mild, and best conditions, appears to affect the VO₂ peak behavior (F=5.90, P=0.004) in a manner whereby, at the best DLCO condition, the VO₂ peak maximizes its performance (1,794.6, Figure 5).

**Discussion**

The major finding of this study was that cardiopulmonary exercise testing revealed limitations in exercise capacity to a similar extent regardless of the radiological stage in patients with sarcoidosis, although PFTs indicated clinical impairment only in patients with more advanced disease. To our knowledge, our retrospective study is the first to

---

**Table 2 Cardiopulmonary exercise test results in 83 patients with sarcoidosis classified according to radiological stage of the disease**

| Maximal exercise data | All (n=83) | Stage I (n=43) | Stage II–III (n=31) | Stage IV (n=9) | P-value |
|-----------------------|-----------|----------------|---------------------|---------------|---------|
| Workload, W           | 97.57±53.630 | 106.20±55.320 | 90.03±52.560 | 82.33±46.600 | 0.135   |
| VO₂ peak, %pred       | 84.60±15.310 | 88.28±14.360 | 82.65±15.120 | 73.78±15.560 | 0.166   |
| VO₂ peak, mL/kg/min   | 20.62±5.661 | 21.96±5.210 | 19.55±5.240 | 17.96±4.250 | 0.098   |
| ΔVO₂/ΔWR, mL/W        | 2.59±1.620 | 2.0±1±0.700 | 21.21±12.330 | 20±6.29±9.725 | 0.174   |
| Vₚ, L/min             | 56.42±20.220 | 58.28±21.900 | 54.32±19.570 | 54.78±13.960 | 0.232   |
| Vₚ/VO₂, VT            | 23.80±4.190 | 23.02±3.650 | 23.77±3.970 | 24.64±4.270 | 0.345   |
| Vₚ/VCO₂, VT           | 26.45±4.660 | 25.80±4.050 | 26.41±4.410 | 30.73±6.260 | 0.223   |
| BF max, min⁻¹         | 39.20±12.000 | 35.70±10.000 | 37.80±11.000 | 42.90±10.000 | 0.356   |
| Vₚ peak, FVC%         | 52.30±25.000 | 51.34±32.000 | 51.20±45.000 | 54.01±56.000 | 0.508   |
| HR peak               | 145.20±23.400 | 149.50±22.660 | 138.90±24.790 | 146.40±18.900 | 0.078   |
| AT                    | 16.11±18.500 | 18.62±25.220 | 13.63±4.820 | 12.62±3.310 | 0.245   |
| Oxygen pulse peak     | 11.06±4.100 | 11.29±4.040 | 11.24±4.510 | 9.36±2.560 | 0.726   |
| ΔHR/ΔVO₂              | 68.83±24.000 | 71.43±25.000 | 65.50±23.000 | 74.67±27.000 | 0.063   |

**Note:** Results are expressed as mean ± standard deviation.

**Abbreviations:** FVC, percent forced vital capacity; %pred, percent predicted; AT, anaerobic threshold; BF, breathing frequency; HR, heart rate; Vₚ, minute ventilation; VCO₂, carbon dioxide production; VO₂, oxygen consumption; Vₚ, tidal volume; VT, ventilatory threshold; WR, workload.
Figure 1 VO$_2$ peak correlations with clinical, functional, and cardiopulmonary test parameters in 83 patients with sarcoidosis.

Note: $P<0.001$ for all comparisons.

Abbreviations: FVC%, percent forced vital capacity; %pred, percent predicted; AT, anaerobic threshold; DLCO, diffusing capacity of the lung for carbon monoxide; V$_e$, minute ventilation; VO$_2$ peak, peak oxygen consumption; V$_T$, tidal volume.

Table 3 Correlation of functional variables at rest with peak oxygen consumption (VO$_2$ peak) in 83 patients with sarcoidosis according to radiological stages

| Variable | Stage I | | | Stage II–III | | | Stage IV | |
|---|---|---|---|---|---|---|---|---|
| | $r$ | $P$ | | $r$ | $P$ | | $r$ | $P$ |
| FEV$_1$ | –0.147 | 0.346 | | 0.395 | 0.028 | | –0.402 | 0.284 |
| FVC | –0.087 | 0.579 | | 0.453 | 0.010 | | –0.368 | 0.330 |
| FEV$_1$/FVC | 0.111 | 0.478 | | 0.045 | 0.809 | | –0.561 | 0.117 |
| FEF$_{25-75}$ | 0.004 | 0.998 | | 0.445 | 0.012 | | –0.207 | 0.594 |
| FRC | –0.653 | 0.423 | | 0.647 | 0.422 | | –0.634 | 0.452 |
| RV | –0.017 | 0.910 | | 0.072 | 0.698 | | –0.536 | 0.782 |
| TLC | 0.088 | 0.574 | | 0.319 | 0.080 | | –0.059 | 0.881 |
| DLCO | 0.397 | 0.008 | | 0.412 | 0.021 | | 0.160 | 0.681 |

Note: Lung function parameters are expressed as percentage of the predicted values.

Abbreviations: DLCO, diffusing capacity of the lung for carbon monoxide; FEF$_{25-75}$, forced expiratory flow 25%–75%; FEV$_1$, forced expiratory volume in 1 second; FRC, functional residual capacity; FVC, forced vital capacity; RV, residual volume; TLC, total lung capacity.
have evaluated exercise capacity in a Greek population of sarcoid patients by combined assessment of PFT and CPET measurements.

Our results are in agreement with the current published literature. Earlier studies reported that abnormal responses of oxygen uptake during exercise are common in sarcoidosis, even in those patients with only mild disease. Akkoca et al in a small study of 29 sarcoid patients, found that exercise capacity was the earliest impaired physiological parameter, even in patients with Stage I disease and completely normal spirometry. Similarly, in another small study of 32 patients with sarcoidosis and variable levels of DLCO, Karetzky and McDonough reported significant exercise intolerance, with an up to 30% reduction in

---

**Figure 2** Biplot of correlation coefficients (loading factors) of ergo/spirometric variables with PCA axes 1 and 2. The longer the arrow the greater effect is produced by the variable. Variables forming oblique angles correlate positively with each other and negatively at arrows with obtuse angles. The lower oblique or wider obtuse aperture the higher the correlation coefficient.

**Abbreviations:** AT, anaerobic threshold; DLCO, diffusing capacity of the lung for carbon monoxide; FEF\textsubscript{25–75}, forced expiratory flow 25%–75%; FEV\textsubscript{1}, forced expiratory volume in 1 second; FVC, forced vital capacity; FVC\%, percent forced vital capacity; HR, heart rate; PCA, principal component analysis; RV\%, percent residual volume; TLC, total lung capacity; V\textsubscript{CO}, carbon dioxide production; V\textsubscript{e}, minute ventilation; VO\textsubscript{2}, oxygen consumption; V\textsubscript{T}, tidal volume; v0m\%, maximal aerobic capacity.

---

**Figure 3** PCA scores and patients position as arranged by the two major axes according to radiological Stages I–III and the combined presence/absence of ecto-pneumonic location and restriction rules.

**Abbreviation:** PCA, principal component analysis.
Figure 4 Mean changes of the significant ergo-/spirometric variables with the radiological conditions 1–3.

Abbreviations: DLCO%, percent diffusing capacity of the lung for carbon monoxide; FEV₁%, percent forced expiratory volume in 1 second; FEF₂₅–₇₅, forced expiratory flow 25%–75%; FVC%, percent forced vital capacity; TLC, total lung capacity; VCO₂, carbon dioxide production; VO₂, oxygen consumption; VO₂ max, maximum oxygen consumption; vom%, maximal aerobic capacity; VR, deadspace; V̇E, minute ventilation; V̇T, tidal volume; vom%, maximal aerobic capacity; HR, heart rate.
maximal aerobic capacity compared to healthy age-matched controls.

In patients with more advanced disease, previous studies suggested that reduced exercise capacity may reflect limitations due to ventilatory mechanics impairment and gas exchange abnormalities. In our study, FEV₁, FVC, TLC, and DLCO were significantly decreased in Stage IV patients, a finding that could probably explain the affected exercise performance, as expressed by the significant decrease in VO₂ peak, in those patients. Our findings are in agreement with the results of Marcellis et al who reported, in their study of 160 sarcoid patients, that DLCO%, FVC%, and advanced radiological stages (0–I vs II–IV) were significantly independent predictors of pulmonary gas exchange abnormalities. Additionally in our study we found that, in Stage IV patients, V<sub>e</sub>/VCO<sub>2</sub> was significantly increased compared to Stage I, suggesting that hyperventilation may also play a role in exercise limitation in more advanced disease. This increase in the ventilatory response in Stage IV may be attributed, at least in part, to inefficient gas exchange due to impairment of the diffusing capacity of the lungs or to increased physiological dead space due to pulmonary hypertension. However, our study was not designed to assess this finding by arterial blood gas measurements or echocardiography.

On the other hand, in the early stages of sarcoidosis, with normal or only mildly impaired lung function, circulatory impairment and reduced heart response to exercise seem to contribute in exercise intolerance. In our study, while DLCO and functional parameters were not affected in Stage I and were only mildly impaired in Stages II–III, 48% of Stage I and 52% of Stage II–III patients, presented an abnormal CPET response. Interestingly, in these patients, exercise capacity, as expressed by VO₂ peak was found to correlate strongly with both ventilatory as well as cardiocirculatory parameters of CPET. Additionally, 26% of our patients did not reach the predicted maximum heart rate in spite of performing a maximal CPET with respect to AT, a fact suggesting that the low HR peak was unlikely to be related to a submaximal study. It is worth noting that, in our study, a significant correlation (P=0.007) was noted between VO₂ peak and HR peak and VO₂ to HR ratio (or oxygen pulse) in Stages II–III, findings that may in part explain the exercise limitation (Table 4). Delobbe et al showed that a low peak heart rate at maximal CPET was associated with reduced maximal exercise capacity in sarcoid patients with normal resting PFT and reductions in HR of similar extent were also reported by Karetzky and McDonough, although the authors did not explain this result. Finally, cardiac dysfunction in sarcoidosis may be secondary to subclinical left heart failure.

![Figure 5 Mean changes of VO₂ peak along with the ordinal categories of diffusing capacity of the lung for carbon monoxide (DLCO).](image)

**Notes:** Vertical lines indicate the 95% confidence intervals of means calculated from the error mean square of analysis of variance. Means whose intervals do not overlap differ significantly.

### Table 4 Correlation of cardiopulmonary test variables with VO₂ peak in 83 patients with sarcoidosis according to radiological stages

| Variable        | Stage I |       | Stage II–III |       | Stage IV |       |
|-----------------|---------|-------|--------------|-------|----------|-------|
|                 | r       | P     | r            | P     | r        | P     |
| Workload        | 0.832   | <0.001| 0.8537       | <0.001| 0.812    | 0.008|
| VO₂ max         | 0.236   | 0.127 | 0.385        | 0.032 | 0.058    | 0.880|
| V<sub>c</sub>CO<sub>2</sub> | 0.794 | <0.001| 0.849        | <0.001| 0.980    | <0.001|
| V<sub>e</sub>   | 0.752   | <0.001| 0.825        | <0.001| 0.979    | <0.001|
| V<sub>e</sub>/VCO<sub>2</sub> | -0.241 | 0.119 | -0.462       | 0.009 | 0.107    | 0.661|
| V<sub>e</sub> peak | 0.662 | <0.001| 0.871        | <0.001| 0.737    | 0.024|
| HR peak         | 0.144   | 0.356 | 0.473        | 0.007 | 0.378    | 0.316|
| AT              | 0.566   | <0.001| 0.689        | <0.001| 0.332    | 0.382|
| Oxygen pulse    | 0.861   | <0.001| 0.838        | <0.001| 0.879    | 0.002|
| ΔHR/ΔVO₂        | -0.573  | 0.008 | -0.683       | <0.001| 0.762    | 0.287|
| ΔVO₂/ΔWR       | -0.322  | 0.035 | -0.582       | <0.001| -0.879   | 0.002|

**Note:** Cardiopulmonary test parameters are expressed as percentage of the predicted values. **Abbreviations:** AT, anaerobic threshold; HR, heart rate; V<sub>c</sub>, minute ventilation; WR, workload; V<sub>c</sub>CO<sub>2</sub>, carbon dioxide production; VO₂, oxygen consumption; VO₂ max, maximum oxygen consumption; V<sub>e</sub>, tidal volume.
system infiltration with sarcoid granulomas, and unrecognized pulmonary hypertension or cor pulmonale that may all also significantly contribute to exercise intolerance. Nevertheless, our suggestions do not exclude the possibility that the observed oxygen pulse decrease might also be related to deconditioning, fatigue, or muscle involvement. The main limitation of our study was that the included data were insufficient to provide information about the exact mechanisms causing exercise intolerance in patients with sarcoidosis. Our study was not designed to demonstrate inefficiency of gas exchange during exercise by arterial gas measurements and potential cardiovascular dysfunction was not documented by echocardiography or other cardiac imaging techniques. Furthermore, confounding factors, such as treatment with corticosteroids, general fatigue, skeletal muscle weakness, and physical inactivity are also often present in sarcoid patients and may have influenced our findings. Moreover, sarcoidosis fatigue syndrome was not assessed by the treating physicians.

Finally, the findings of the present study need to be reproduced prospectively in a larger sample, especially with more Stage IV patients, so that definite conclusions can be made.

Conclusion
The results of our study confirm the added value of cardiopulmonary exercise testing in the evaluation of exercise intolerance in patients with sarcoidosis. The analysis of our data suggests that exercise capacity is the earliest impaired physiological parameter in sarcoid patients, as it was found to be reduced even in the early stages of the disease. The mechanisms responsible for exercise limitation in sarcoidosis have a multifactorial basis and seem to be correlated with the radiological extent of the disease. In more advanced stages, ventilatory and gas exchange abnormalities are probably primarily responsible for reduced exercise performance. However, in the earlier stages, cardiocirculatory factors – in particular, impaired HR response to exercise – were found to contribute to a significant degree to exercise intolerance, a fact that underlines the usefulness of CPET in determining the possible pathogenetic mechanisms. Prospective clinical studies with larger series of all stages are needed to define the mechanisms of exercise intolerance in sarcoidosis. It is the belief of the authors that cardiopulmonary exercise testing should be performed in every patient presenting with sarcoidosis and on follow-up, if available.

Disclosure
The authors declare no conflicts of interest in this work.

References
1. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160(2): 736–755.
2. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med. 2011;183(5):573–581.
3. Drent M, Lower EE, De Vries J. Sarcoidosis-associated fatigue. Eur Respir J. 2012;40(1):255–263.
4. Marcellis RG, Lenssen AF, Elfferich MD, et al. Exercise capacity, muscle strength and fatigue in sarcoidosis. Eur Respir J. 2011;38(3):628–634.
5. Winterbauer RH, Hutchinson JF. Use of pulmonary function tests in the management of sarcoidosis. Chest. 1980;78(4):640–647.
6. Levinson RS, Metzger LF, Stanley NN, et al. Airway function in sarcoidosis. Am J Med. 1977;62(1):51–59.
7. Delobbe A, Perraunt H, Mairet J, et al. Impaired exercise response in sarcoid patients with normal pulmonary function. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases: Official Journal of WASOG/World Association of Sarcoidosis and Other Granulomatous Disorders. 2002;19(2):148–153.
8. Kollett F, Geck B, Suchy R, et al. The impact of gas exchange measurement during exercise in pulmonary sarcoidosis. Respir Med. 2011;105(1):122–129.
9. Athos L, Mohler JG, Sharma OP. Exercise testing in the physiologic assessment of sarcoidosis. Ann N Y Acad Sci. 1986;465:491–501.
10. Miller A, Brown LK, Sloane MF, Bhuptani A, Teirstein AS. Cardiorespiratory responses to incremental exercise in sarcoidosis patients with normal spirometry. Chest. 1995;107(2):323–329.
11. Cotes JE. Medical Research Council Questionnaire on Respiratory Symptoms (1986). Lancet. 1987;2(8566):1028.
12. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993;16:5–40.
13. Macintyre N, Crapo RO, Viegi G, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2005;26(4):720–735.
14. American Thoracic Society; American College of Chest Physicians. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2003;167(2):211–277.
15. Spiro SG, Dowdeswell IR, Clark TJ. An analysis of submaximal exercise responses in patients with sarcoidosis and fibrosing alveolitis. Br J Dis Chest. 1981;75(2):169–180.
16. Matthews JJ, Hooper RG. Exercise testing in pulmonary sarcoidosis. Chest. 1983;83(1):75–81.
17. Akkoca O, Celik G, Ulger F, et al. Exercise capacity in sarcoidosis. Study of 29 patients. Med Clin (Barc). 2005;124(18):686–689.
18. Karetzky M, McDonough M. Exercise and resting pulmonary function in sarcoidosis. Sarcoidosis Vasculitis Diffuse Lung Dis. 1996;13(1):43–49.
19. Wallaert B, Tallevu C, Wemeau-Stervinou L, Duhamel A, Robin S, Aguilaniu B. Reduction of maximal oxygen uptake in sarcoidosis: relationship with disease severity. Respiration. 2011;82(6):501–508.
20. Barros WG, Neder JA, Pereira CA, Nery LE. Clinical, radiographic and functional predictors of pulmonary gas exchange impairment at moderate exercise in patients with sarcoidosis. Respir Physiol Neurobiol. 2000;121(4):367–373.
21. Marcellis RG, Lenssen AF, de Vries GJ, et al. Is there an added value of cardio-pulmonary exercise testing in sarcoidosis patients? Lung. 2013;191(1):43–52.
22. Péronnet F, Aguilaniu B. Lactic acid buffering, nonmetabolic CO2 and exercise hyperventilation: a critical reappraisal. Respir Physiol Neurobiol. 2006;150(1):4–18.
23. Baughman RP, Engel PJ, Meyer CA, Barrett AB, Lower EE. Pulmonary hypertension in sarcoidosis. *Sarcoidosis Vascul Diffuse Lung Dis*. 2006;23(2):108–116.

24. Medinger AE, Khouri S, Rohatgi PK. Sarcoidosis: the value of exercise testing. *Chest*. 2001;120(1):93–101.

25. Sietsema KE, Kraft M, Ginzton L, Sharma OP. Abnormal oxygen uptake responses to exercise in patients with mild pulmonary sarcoidosis. *Chest*. 1992;102(3):838–845.

26. Sharma OP, Maheshwari A, Thaker K. Myocardial sarcoidosis. *Chest*. 1993;103(1):251–258.

27. Lopes AJ, Menezes SL, Dias CM, Oliveira JF, Mainenti MR, Guimarães FS. Cardiopulmonary exercise testing variables as predictors of long-term outcome in thoracic sarcoidosis. *Braz J Med Biol Res*. 2012;45(3):256–263.

28. Marcellis RG, Lenssen AF, Kleynen S, De Vries J, Drent M. Exercise capacity, muscle strength, and fatigue in sarcoidosis: a follow-up study. *Lung*. 2013;191(3):247–256.

29. Spruit MA, Thomeer MJ, Gosselink R, et al. Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. *Thorax*. 2005;60(1):32–38.

30. Baydur A, Alsalek M, Louie SG, Sharma OP. Respiratory muscle strength, lung function, and dyspnea in patients with sarcoidosis. *Chest*. 2001;120(1):102–108.